RaySearch Laboratories AB (publ)
RaySearch Laboratories AB (publ)
Your view on RSLBF
Overview
What the company does, where it operates, and who runs it.
About RaySearch Laboratories AB (publ)
- Industry
- Medical - Healthcare Information Services
- Sector
- Healthcare
- CEO
- Johan Lof
- Headquarters
- Sveavägen 44, Stockholm, SE
- Industry
- Medical - Healthcare Information Services
- Sector
- Healthcare
- CEO
- Johan Lof
- Headquarters
- Sveavägen 44, Stockholm, SE
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment worldwide.
It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, OAR dose reduction, robustness, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy.
The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information system to support cancer treatment activities.
In addition, it offers RayCommand, a treatment control system that is compatible with various hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights.
Further, the company provides training courses related to its products. RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for RaySearch Laboratories AB (publ), and the rating behind it. RSLBF last traded at $23.00, 28.5× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for RaySearch Laboratories AB (publ). Starting points for RaySearch Laboratories AB (publ): P/E 28.5, EPS $6.22, beta 1.07 — an Medical - Healthcare Information Services name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for RaySearch Laboratories AB (publ). RaySearch Laboratories AB (publ) does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for RaySearch Laboratories AB (publ). Trailing twelve-month EPS for RaySearch Laboratories AB (publ) stands at $6.22. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for RaySearch Laboratories AB (publ). RaySearch Laboratories AB (publ) has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
RaySearch Laboratories AB (publ) valued side by side against its closest peers. RaySearch Laboratories AB (publ) is measured against Medical - Healthcare Information Services peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold RaySearch Laboratories AB (publ), and how their positions are changing. At a $822.2M market value, institutional positions materially move RaySearch Laboratories AB (publ)'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by RaySearch Laboratories AB (publ) executives and directors. Shares of RaySearch Laboratories AB (publ) have traded between $20.60 and $37.36 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming RaySearch Laboratories AB (publ). RaySearch Laboratories AB (publ) is a $822.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming RaySearch Laboratories AB (publ). Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for RaySearch Laboratories AB (publ). Coverage tracks RaySearch Laboratories AB (publ) within Medical - Healthcare Information Services (Healthcare). Press releases and market coverage, newest first.